Clear visual breakdown: for every ₹100 earned, see how much flows to salaries, operating costs, government taxes, EPS profit, and your share.
Profit Conversion
₹9.8/ ₹100
Moderate volume margin
Human Capital & Talent
₹12.0/ ₹100
Workforce salaries, engineers & talent
Earnings Per Share (EPS)
₹19.25/ share
Annual profit generated per stock unit
Shareholder Payout
₹3.5/ ₹100
Direct cash dividends & buybacks
Multi-Stage Money Stream (Sankey Flow)
Hover or drag nodes to inspect connections and money volumeMode: Every ₹100 Company Sales
Revenue
Materials / Production
Human Capital (Talent)
Government Taxes
Net Profit / EPS
Dividends & Reinvestment
Topline Money Inflow100.0%
Gross Commercial Revenue
₹100.00per ₹100 sales
For every ₹100 collected by AARTI PHARMALABS LIMITED from customers and clients globally.
Raw Materials, Energy & Inventory55.7%
Direct Production & Materials (COGS)
₹55.69per ₹100 sales
Direct physical costs required to produce the company's products, chip fabrication, server components, or merchandise.
Salaries, Benefits, R&D & Talent12.0%
Human Capital & Engineering Workforce
₹12.00per ₹100 sales
Compensation paid to software engineers, technicians, designers, operators, and staff driving the business forward.
Cloud Servers, Sales, Marketing & Legal25.9%
Operating, Tech & Administrative (SG&A)
₹25.87per ₹100 sales
Essential business operations including data center infrastructure, global marketing, compliance, and office facilities.
Interest to Bank Lenders & Bondholders2.6%
Debt Servicing & Financing Costs
₹2.62per ₹100 sales
Cost of borrowed capital. Lower interest outlays indicate low debt dependency and strong financial solvency.
Direct Corporate Tax Paid to State3.3%
Government Corporate Taxes
₹3.26per ₹100 sales
Statutory income taxes contributed to national infrastructure, roads, defense, and public governance.
Pure Profit Belongs to Shareholders9.8%
Net Bottom-Line Profit (EPS Engine)
₹9.77per ₹100 sales
The ultimate earnings of the company. This forms your Diluted EPS (₹19.25/share) and belongs entirely to equity owners.
Cash Deposited to Investor Bank Accounts2.0%
Direct Cash Dividends
₹2.03per ₹100 sales
Actual liquid profits credited directly into your brokerage or bank account as passive dividend cash flow.
Reduces Share Count to Elevate EPS1.5%
Share Repurchases (Buybacks)
₹1.47per ₹100 sales
The company buys its own shares off the market and retires them, making your remaining shares represent a larger slice of future profits.
Reinvested in New Factories, AI & Tech25.1%
Capital Expenditure (Growth CapEx)
₹25.08per ₹100 sales
Long-term capital assets purchased: next-gen server clusters, robotics, retail stores, or production assembly lines.
Retained Earnings on Balance Sheet6.3%
Treasury Reserves & War Chest
₹6.27per ₹100 sales
Cash reserves stored in bank deposits, treasuries, and safe liquid investments to withstand crises and fund sudden strategic acquisitions.
Shareholder Capital Simulator: Where Does Your Investment Go?
Select or type any investment amount to see how much commercial activity and earnings your money commands in AARTI PHARMALABS LIMITED.
Your Investment:₹50,000 (~53.8 shares at ₹929.1/share)
Annual Revenue
₹10,603
Generated by your capital
Human Capital
₹1,272
Engineers & staff salaries
Taxes Paid
₹345
Public infrastructure
Your Net Earnings
₹1,036
Annual profit earned by you (2.1% yield)
Cash Dividend
₹215
Direct cash to your bank
Growth CapEx
₹2,659
Reinvested in tech & expansion
How to read this flow diagram as an investor:Revenue represents gross sales (₹100). Before any profit can reach you, the company must first pay suppliers (COGS), its workforce & engineers (Human Capital), rent & technology (SG&A), lenders (Interest), and the government (Taxes). What remains is Net Profit (Diluted EPS). Healthy companies divide this profit between Cash Dividends, Share Buybacks (retiring shares to boost your percentage ownership), and CapEx Reinvestment to build new capacity for future years.
Key Fundamentals & Ratios
Real-Time Screener Matrix
Market Cap
₹8,425 Cr
Mid Cap
Current Price
₹929.10
+0.09% today
52W High / Low
₹1002.4 / ₹585
Past 52 weeks historical
Stock P/E
32.9
Forward: 36.4
Book Value
₹234.28
Price to Book: 3.97x
Dividend Yield
0.43%
Annualised distribution
Return on Equity (ROE)
—
Shareholder returns efficiency
1-Year Return
+7.32%
52W change percent
52W Low: ₹585.00Current price sits at 82% of 52W range52W High: ₹1,002.40
About AARTI PHARMALABS LIMITED
Healthcare & Pharma
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates, such as xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. It serves pharmaceutical, nutraceutical, and beverage industries. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
TTM Revenue₹1,969 Cr
Net Profit Margin10.4%
Operating Margin19.2%
EPS (Trailing)₹28.27
Peer Comparison
Comparing AARTI PHARMALABS LIMITED with leading competitors in Healthcare & Pharma (Indian Market)
Data Provenance & Regulatory DisclosureSource: NSE/BSE Statutory Filings
Quotes are delayed by at least 15 minutes. Financial metrics and disclosures are cross-referenced with periodic statutory disclosures from the National Stock Exchange of India (NSE) and BSE India. This content is provided strictly for educational and portfolio analytics purposes, and does not constitute investment advice or Buy/Sell recommendations.
